▁Introduction 10.375
: 6.51953125
<0x0A> 3.98046875
M 4.5390625
el 3.826171875
an 3.66015625
oma 0.787109375
, 2.953125
▁a 2.033203125
▁type 1.8271484375
▁of 0.00412750244140625
▁skin 0.166015625
▁cancer 0.004863739013671875
, 0.16552734375
▁is 0.470947265625
▁a 2.31640625
▁serious 2.5625
▁health 2.275390625
▁concern 1.4736328125
▁that 1.8837890625
▁affect 2.216796875
s 0.0017948150634765625
▁individuals 5.40625
▁of 0.90380859375
▁all 0.10699462890625
▁ages 0.312255859375
. 0.435302734375
▁However 3.185546875
, 0.006526947021484375
▁recent 5.3515625
▁adv 3.08203125
anc 0.8662109375
ements 5.9604644775390625e-05
▁in 0.1739501953125
▁mel 1.41796875
an 0.00029587745666503906
oma 0.004047393798828125
▁treatment 1.291015625
▁have 0.626953125
▁brought 4.8046875
▁hope 1.5654296875
▁to 0.317138671875
▁patients 1.2705078125
▁by 4.75390625
▁en 4.10546875
han 0.59765625
cing 3.5762786865234375e-05
▁long 5.78125
- 0.05364990234375
term 0.082763671875
▁rem 6.0859375
ission 0.302001953125
▁rates 0.51025390625
. 0.8203125
▁Im 6.18359375
m 2.029296875
une 0.4052734375
▁check 0.54248046875
point 0.020660400390625
▁in 0.1639404296875
hib 0.00021541118621826172
itors 0.11944580078125
▁and 3.767578125
▁adj 6.37890625
uv 0.021148681640625
ant 0.006214141845703125
▁ther 0.5078125
ap 0.48681640625
ies 0.0001093149185180664
▁have 1.0068359375
▁emer 4.23828125
ged 0.0006875991821289062
▁as 0.0264892578125
▁ground 6.75390625
bre 0.11041259765625
aking 0.00034737586975097656
▁treatment 1.9658203125
▁options 0.73388671875
, 2.572265625
▁revolution 5.04296875
izing 0.0160064697265625
▁the 0.68994140625
▁landscape 3.689453125
▁of 0.07293701171875
▁mel 0.1993408203125
an 0.00024330615997314453
oma 0.0016145706176757812
▁treatment 1.1240234375
▁and 2.33203125
▁impro 1.5732421875
ving 0.00013446807861328125
▁surv 2.162109375
ival 0.01358795166015625
▁rates 0.2744140625
. 0.4150390625
▁This 2.974609375
▁ess 7.48046875
ay 0.0008578300476074219
▁will 0.66357421875
▁explore 1.77734375
▁the 0.2420654296875
▁imp 5.23828125
lications 0.08941650390625
▁of 0.093505859375
▁these 1.583984375
▁treat 2.490234375
ments 8.52346420288086e-05
▁for 2.0
▁patients 0.7119140625
▁at 5.515625
▁different 2.197265625
▁stages 0.32666015625
▁of 0.064453125
▁mel 1.4453125
an 5.8650970458984375e-05
oma 0.00244903564453125
, 1.6572265625
▁using 5.8828125
▁Mr 11.9609375
. 0.142333984375
▁B 4.43359375
' 3.240234375
s 0.002277374267578125
▁case 1.40234375
▁as 0.30908203125
▁an 0.2861328125
▁exempl 4.83984375
ar 0.26513671875
, 5.54296875
▁alongside 5.69921875
▁research 5.23046875
▁evidence 4.20703125
. 1.5068359375
<0x0A> 0.57080078125
Body 7.828125
: 3.240234375
<0x0A> 1.67578125
1 3.42578125
. 0.200439453125
▁Im 3.609375
m 0.11541748046875
une 0.01160430908203125
▁Check 0.9482421875
point 0.034912109375
▁In 0.0450439453125
hib 0.0004658699035644531
itors 0.07171630859375
: 2.095703125
<0x0A> 0.2337646484375
▁▁ 13.4765625
▁Im 2.5234375
m 0.060882568359375
une 0.00495147705078125
▁check 0.0655517578125
point 0.029876708984375
▁in 0.01120758056640625
hib 0.0005292892456054688
itors 0.0240936279296875
, 2.251953125
▁such 1.9541015625
▁as 0.0033111572265625
▁p 1.701171875
emb 0.0014448165893554688
rol 0.002918243408203125
iz 0.003047943115234375
um 0.0027828216552734375
ab 0.0003218650817871094
▁and 1.107421875
▁n 0.07391357421875
iv 0.0013151168823242188
ol 0.0004494190216064453
um 0.00115966796875
ab 0.0012683868408203125
, 0.05792236328125
▁work 4.375
▁by 0.1505126953125
▁un 6.28515625
le 0.8134765625
ash 0.0002493858337402344
ing 8.857250213623047e-05
▁the 0.1683349609375
▁body 0.7041015625
' 0.00782012939453125
s 0.00033974647521972656
▁imm 0.98828125
une 0.0025577545166015625
▁system 0.09442138671875
▁to 0.5224609375
▁fight 1.419921875
▁cancer 0.426025390625
▁cells 0.459716796875
. 0.2144775390625
▁These 1.2080078125
▁in 3.7109375
hib 0.00566864013671875
itors 0.0193634033203125
▁block 1.2607421875
▁prote 3.76953125
ins 0.0005130767822265625
▁that 1.96875
▁prevent 1.5009765625
▁T 2.228515625
▁cells 0.54541015625
▁from 0.1966552734375
▁attack 1.076171875
ing 1.823902130126953e-05
▁cancer 0.5244140625
▁cells 0.08538818359375
, 0.88427734375
▁rein 11.515625
for 0.0560302734375
cing 0.0028743743896484375
▁the 0.36962890625
▁imm 0.826171875
une 0.0029964447021484375
▁response 1.2841796875
▁against 1.494140625
▁mel 1.4345703125
an 0.0001226663589477539
oma 0.02008056640625
. 0.71630859375
<0x0A> 1.5029296875
▁▁ 1.0771484375
▁- 7.34375
▁In 4.15625
▁Mr 4.53125
. 0.045562744140625
▁B 0.0452880859375
' 0.143798828125
s 0.002208709716796875
▁case 0.0282745361328125
, 0.033935546875
▁who 7.46484375
▁was 1.5576171875
▁diagn 0.49609375
osed 0.0004372596740722656
▁with 0.050750732421875
▁stage 1.4609375
▁III 1.6591796875
▁mel 1.0458984375
an 9.429454803466797e-05
oma 0.0006566047668457031
, 0.97119140625
▁imm 2.271484375
une 0.1878662109375
▁check 0.01071929931640625
point 0.007274627685546875
▁in 0.01013946533203125
hib 0.0001938343048095703
itors 0.047943115234375
▁hold 10.2109375
▁the 1.509765625
▁potential 1.3486328125
▁to 0.27490234375
▁enh 2.7109375
ance 8.249282836914062e-05
▁his 2.9921875
▁long 0.88037109375
- 0.01410675048828125
term 0.0011348724365234375
▁rem 0.9990234375
ission 0.0020904541015625
▁prospect 6.0390625
s 0.0228118896484375
. 0.6396484375
▁By 3.8515625
▁boost 3.755859375
ing 0.00011324882507324219
▁his 1.7451171875
▁imm 0.2489013671875
une 0.0122833251953125
▁system 0.266845703125
, 0.908203125
▁these 0.61181640625
▁in 1.2333984375
hib 0.002391815185546875
itors 0.00612640380859375
▁may 1.376953125
▁target 5.875
▁any 4.98046875
▁remaining 1.19140625
▁cancer 0.3134765625
▁cells 0.0567626953125
, 1.62890625
▁reducing 3.95703125
▁the 0.354736328125
▁ch 2.66796875
ances 0.00012624263763427734
▁of 0.10577392578125
▁rec 1.01171875
urrence 0.025421142578125
. 0.7919921875
<0x0A> 0.56689453125
▁▁ 0.3662109375
▁- 0.31640625
▁A 4.5859375
▁study 3.1796875
▁by 2.361328125
▁Long 7.83984375
▁et 2.07421875
▁al 0.03729248046875
. 0.21923828125
▁( 1.1787109375
2 0.02130126953125
0 0.00417327880859375
1 0.60693359375
9 1.384765625
) 0.0819091796875
▁demonstrated 2.81640625
▁that 0.274169921875
▁combining 5.6875
▁imm 1.40625
une 0.08197021484375
▁check 0.028961181640625
point 0.00402069091796875
▁in 0.026214599609375
hib 7.2479248046875e-05
itors 0.08050537109375
▁with 0.2021484375
▁standard 3.26953125
▁treat 2.775390625
ments 0.00012028217315673828
▁resulted 3.275390625
▁in 0.0005888938903808594
▁significantly 3.353515625
▁improved 1.203125
▁surv 1.486328125
ival 0.0010738372802734375
▁rates 0.343017578125
▁for 1.6083984375
▁patients 0.414306640625
▁with 0.14111328125
▁stage 1.5615234375
▁III 0.15576171875
▁mel 0.1749267578125
an 5.733966827392578e-05
oma 0.005016326904296875
, 2.56640625
▁p 6.703125
aving 0.0400390625
▁the 0.0238189697265625
▁way 0.01340484619140625
▁for 0.06781005859375
▁highly 8.078125
▁prom 2.765625
ising 0.00020420551300048828
▁th 4.53125
era 0.0002570152282714844
pe 1.4901161193847656e-05
ut 2.4199485778808594e-05
ic 0.048126220703125
▁approaches 3.470703125
. 0.6865234375
<0x0A> 0.2149658203125
2 2.01953125
. 0.00768280029296875
▁Ad 0.163818359375
j 0.01202392578125
uv 0.0005707740783691406
ant 0.0006265640258789062
▁Ther 0.06622314453125
ap 0.59033203125
ies 0.0001310110092163086
: 0.049072265625
<0x0A> 0.023681640625
▁▁ 0.2529296875
▁Ad 0.88720703125
j 0.0011587142944335938
uv 0.0005655288696289062
ant 0.0011234283447265625
▁ther 0.0628662109375
ap 0.25927734375
ies 2.181529998779297e-05
, 1.5908203125
▁such 0.72265625
▁as 0.0020885467529296875
▁target 5.52734375
ed 0.005542755126953125
▁ther 0.53076171875
apy 0.84423828125
▁and 0.73681640625
▁imm 1.56640625
un 0.2236328125
other 0.01534271240234375
apy 0.0139007568359375
, 0.0187530517578125
▁are 1.05859375
▁admin 3.076171875
ister 0.0003077983856201172
ed 0.00011646747589111328
▁after 0.490478515625
▁primary 3.095703125
▁treat 3.416015625
ments 8.64267349243164e-05
▁to 0.92529296875
▁eliminate 5.6171875
▁any 1.287109375
▁resid 1.7958984375
ual 0.0019063949584960938
▁cancer 0.379150390625
▁cells 0.034393310546875
, 2.90625
▁lower 5.98046875
ing 0.501953125
▁the 0.06854248046875
▁ch 1.796875
ances 6.389617919921875e-05
▁of 0.01009368896484375
▁re 2.1796875
lapse 0.15478515625
. 0.55126953125
<0x0A> 1.2734375
▁▁ 0.050140380859375
▁- 0.1600341796875
▁In 1.783203125
▁advanced 9.1953125
▁mel 0.335693359375
an 0.00012934207916259766
oma 0.0212554931640625
▁cases 2.123046875
, 0.1324462890625
▁combining 6.9921875
▁adj 0.88623046875
uv 0.0013742446899414062
ant 0.0004189014434814453
▁ther 0.06378173828125
ap 0.1878662109375
ies 9.298324584960938e-06
▁with 0.233154296875
▁imm 0.35009765625
une 0.319091796875
▁check 0.00974273681640625
point 0.00186920166015625
▁in 0.0025653839111328125
hib 2.8371810913085938e-05
itors 0.0188446044921875
▁has 2.400390625
▁been 1.0576171875
▁found 2.34765625
▁to 0.033599853515625
▁be 2.560546875
▁particularly 3.0
▁effective 0.509765625
. 1.7626953125
▁Assuming 12.546875
▁Mr 1.923828125
. 0.006511688232421875
▁B 0.01245880126953125
▁progress 6.9375
es 0.09429931640625
▁to 0.6025390625
▁stage 0.353271484375
▁IV 0.041839599609375
▁mel 0.318359375
an 7.486343383789062e-05
oma 0.0005512237548828125
, 0.255859375
▁this 3.310546875
▁combination 0.765625
▁may 1.5498046875
▁offer 2.328125
▁further 3.837890625
▁hope 1.80078125
▁for 0.447265625
▁long 1.9716796875
- 0.006633758544921875
term 0.00894927978515625
▁rem 0.6884765625
ission 0.0216522216796875
▁by 4.140625
▁not 7.890625
▁only 0.09283447265625
▁elimin 2.408203125
ating 2.9802322387695312e-05
▁remaining 3.125
▁cancer 0.11737060546875
▁cells 0.0224761962890625
▁but 0.46337890625
▁also 0.039459228515625
▁hal 5.09765625
ting 0.004932403564453125
▁the 1.076171875
▁spread 1.6318359375
▁of 0.033416748046875
▁the 1.2333984375
▁disease 0.07513427734375
. 0.41357421875
<0x0A> 0.0406494140625
▁▁ 0.6494140625
▁- 0.035003662109375
▁Research 3.126953125
▁conducted 3.83203125
▁by 0.0528564453125
▁Hass 8.3671875
el 2.41796875
▁et 3.140625
▁al 0.0023784637451171875
. 0.03338623046875
▁( 0.06634521484375
2 0.0028285980224609375
0 9.97781753540039e-05
1 0.51416015625
9 0.9990234375
) 0.02203369140625
▁demonstrated 1.6171875
▁that 0.1766357421875
▁the 2.75390625
▁use 2.064453125
▁of 0.001705169677734375
▁adj 0.79638671875
uv 0.0014209747314453125
ant 0.0009737014770507812
▁imm 2.46875
un 0.4345703125
other 0.004192352294921875
apy 0.1607666015625
▁post 4.83984375
- 0.666015625
s 1.88671875
urg 0.0027332305908203125
ical 2.451171875
▁res 2.052734375
ection 0.007843017578125
▁significantly 3.125
▁impro 2.693359375
ves 0.0004811286926269531
▁surv 1.4765625
ival 0.0004076957702636719
▁rates 0.2073974609375
▁and 3.3203125
▁reduces 1.8828125
▁the 0.32080078125
▁risk 0.57177734375
▁of 0.01207733154296875
▁re 2.392578125
lapse 0.01152801513671875
▁in 0.99658203125
▁high 5.5234375
- 0.0355224609375
ris 0.03631591796875
k 1.5616416931152344e-05
▁stage 2.798828125
▁III 1.4609375
▁mel 0.1927490234375
an 6.23464584350586e-05
oma 0.035736083984375
▁patients 0.3330078125
. 0.1427001953125
<0x0A> 0.1324462890625
Con 5.3125
clusion 0.08636474609375
: 0.11383056640625
<0x0A> 0.66455078125
The 2.72265625
▁adv 3.154296875
anc 0.55224609375
ements 3.325939178466797e-05
▁in 0.268310546875
▁mel 0.293212890625
an 0.00011432170867919922
oma 0.00067901611328125
▁treatment 0.081298828125
, 3.3046875
▁primarily 5.9140625
▁through 2.021484375
▁imm 1.1923828125
une 0.49365234375
▁check 0.00984954833984375
point 0.003032684326171875
▁in 0.0053863525390625
hib 7.903575897216797e-05
itors 0.038909912109375
▁and 0.34375
▁adj 0.00679779052734375
uv 0.0014190673828125
ant 0.0015249252319335938
▁ther 0.0293426513671875
ap 0.042694091796875
ies 2.1338462829589844e-05
, 0.020294189453125
▁have 0.39990234375
▁revolution 1.9482421875
ized 0.0250244140625
▁the 0.115478515625
▁prospect 7.91015625
s 0.0924072265625
▁for 0.89599609375
▁long 3.6015625
- 0.0036106109619140625
term 0.0007777214050292969
▁rem 0.42333984375
ission 0.00626373291015625
, 3.3984375
▁ign 10.3125
iting 0.064697265625
▁hope 0.206298828125
▁for 0.76025390625
▁patients 0.49365234375
▁at 1.322265625
▁all 1.0732421875
▁stages 0.0733642578125
▁of 0.11566162109375
▁mel 0.69287109375
an 7.772445678710938e-05
oma 0.001827239990234375
. 0.1519775390625
▁By 2.77734375
▁target 2.849609375
ing 0.0008511543273925781
▁the 1.654296875
▁imm 1.0322265625
une 0.0111541748046875
▁system 0.083740234375
▁to 1.5830078125
▁combat 2.55078125
▁cancer 0.3544921875
▁cells 0.30126953125
▁and 2.62109375
▁admin 5.62109375
ister 0.00011682510375976562
▁post 8.6484375
- 0.0479736328125
s 0.8173828125
urg 9.179115295410156e-06
ery 2.07421875
▁treat 2.392578125
ments 4.184246063232422e-05
, 0.59716796875
▁these 0.36865234375
▁innov 2.208984375
ative 0.845703125
▁ther 0.61181640625
ap 0.0031757354736328125
ies 1.6927719116210938e-05
▁hold 2.29296875
▁trem 3.71484375
end 6.103515625e-05
ous 0.0007448196411132812
▁potential 0.70166015625
▁for 0.8642578125
▁en 3.158203125
han 0.0640869140625
cing 1.2993812561035156e-05
▁surv 1.03125
ival 0.00519561767578125
▁rates 0.1190185546875
. 2.13671875
<0x0A> 1.091796875
In 4.15234375
▁Mr 3.5859375
. 0.01493072509765625
▁B 0.037139892578125
' 0.033416748046875
s 0.0016841888427734375
▁case 0.024658203125
, 0.020172119140625
▁the 2.640625
▁jud 9.734375
icious 1.30859375
▁util 4.84375
ization 0.0728759765625
▁of 0.004970550537109375
▁imm 0.7890625
une 0.05780029296875
▁check 0.01129913330078125
point 0.002582550048828125
▁in 0.00397491455078125
hib 2.6464462280273438e-05
itors 0.010650634765625
▁and 0.2261962890625
▁adj 0.0088958740234375
uv 0.00139617919921875
ant 0.0011701583862304688
▁ther 0.07232666015625
ap 0.0217132568359375
ies 1.5854835510253906e-05
▁could 3.07421875
▁significantly 2.466796875
▁improve 0.56591796875
▁his 0.8447265625
▁ch 2.5859375
ances 0.00017201900482177734
▁of 0.331787109375
▁ach 4.57421875
ieving 5.364418029785156e-05
▁a 1.8974609375
▁long 0.2392578125
- 0.033233642578125
term 0.01239013671875
▁rem 0.341552734375
ission 0.00043845176696777344
. 0.90087890625
▁Furthermore 4.01171875
, 0.00042247772216796875
▁research 2.234375
▁evidence 1.1591796875
▁supports 3.0703125
▁the 0.35546875
▁consistent 8.9375
▁positive 4.3359375
▁out 1.166015625
comes 0.0189361572265625
▁observed 3.13671875
, 4.3671875
▁suggesting 2.666015625
▁that 0.44873046875
▁these 0.80908203125
▁treat 0.92724609375
ments 7.605552673339844e-05
▁may 1.4384765625
▁become 4.1484375
▁standard 1.6943359375
▁practice 2.365234375
▁for 1.06640625
▁mel 1.8037109375
an 4.57763671875e-05
oma 0.00688934326171875
▁treatment 1.2548828125
▁across 5.84375
▁the 0.4716796875
▁medical 4.95703125
▁community 0.7509765625
. 0.41552734375
<0x0A> 0.56298828125
As 3.810546875
▁we 4.5234375
▁continue 1.376953125
▁to 0.12261962890625
▁expand 4.45703125
▁our 0.351318359375
▁understanding 1.119140625
▁of 0.0352783203125
▁the 1.3330078125
▁imm 3.3984375
une 0.0189666748046875
▁system 0.045013427734375
' 3.634765625
s 0.00038504600524902344
▁role 0.382568359375
▁in 0.007030487060546875
▁fighting 3.908203125
▁cancer 0.08203125
, 0.280517578125
▁it 2.890625
▁is 0.83642578125
▁evident 3.45703125
▁that 0.006988525390625
▁imm 1.708984375
une 0.84375
▁check 0.0178375244140625
point 0.004199981689453125
▁in 0.00786590576171875
hib 1.8477439880371094e-05
itors 0.00995635986328125
▁and 0.2105712890625
▁adj 0.005706787109375
uv 0.0004038810729980469
ant 0.0008153915405273438
▁ther 0.0301971435546875
ap 0.01299285888671875
ies 6.318092346191406e-06
▁are 2.017578125
▁the 4.0390625
▁pill 8.3046875
ars 0.0714111328125
▁of 0.319580078125
▁hope 3.28125
, 4.44140625
▁prom 4.4609375
ising 0.04180908203125
▁a 2.134765625
▁br 0.72412109375
ighter 3.147125244140625e-05
▁future 0.046722412109375
▁for 0.043609619140625
▁mel 1.4208984375
an 9.512901306152344e-05
oma 0.0021190643310546875
▁patients 0.07305908203125
. 0.46337890625
▁By 3.056640625
▁invest 6.33203125
ing 0.0002162456512451172
▁in 0.1182861328125
▁on 5.8203125
going 0.0487060546875
▁research 0.1025390625
▁and 0.7060546875
▁clin 3.748046875
ical 0.0029163360595703125
▁tri 0.070556640625
als 5.4955482482910156e-05
, 0.2861328125
▁we 0.57470703125
▁can 0.267578125
▁push 6.04296875
▁the 0.54541015625
▁boundaries 0.332275390625
▁of 0.035919189453125
▁medical 3.14453125
▁innov 1.935546875
ation 0.0280914306640625
, 1.515625
▁potentially 6.24609375
▁transform 3.611328125
ing 0.0009760856628417969
▁mel 1.841796875
an 4.208087921142578e-05
oma 0.0021648406982421875
▁from 4.390625
▁a 0.07855224609375
▁h 9.0390625
arrow 0.028717041015625
ing 0.0027713775634765625
▁diagn 0.91064453125
osis 0.000885009765625
▁to 0.50048828125
▁a 0.1768798828125
▁manage 0.591796875
able 0.00055694580078125
▁disease 1.494140625
. 0.2666015625
